deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03480152

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Colon Cancer Gastrointestinal Cancer Genitourinary Cancer Hepatocellular Cancer Melanoma
Interventions National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine
Updated 19 times since 2018 Last updated: May 22, 2020 Started: May 18, 2018 Primary completion: Jun 25, 2019 Completion: Nov 5, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

slow accrual

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Colon Cancer trials with similar outcome

Browse all Colon Cancer trials

Listed as NCT03480152, this PHASE1/PHASE2 trial focuses on Colon Cancer and Gastrointestinal Cancer and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 19 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Jul 2019 · 4 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~May 2020 · 5 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Jul 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  5. May 2020 — Jul 2020 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 14 earlier versions

  1. Dec 2019 — May 2020 [monthly]

    Terminated PHASE1_PHASE2

    Status: Completed → Terminated

  2. Oct 2019 — Dec 2019 [monthly]

    Completed PHASE1_PHASE2

  3. Sep 2019 — Oct 2019 [monthly]

    Completed PHASE1_PHASE2

  4. Aug 2019 — Sep 2019 [monthly]

    Completed PHASE1_PHASE2

  5. Jul 2019 — Aug 2019 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  6. Mar 2019 — Jul 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

  9. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  12. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  13. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  14. Apr 2018 — May 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations